Mesenchymal Stromal Cell Committee


The Mesenchymal Stromal Cell Committee strives to:

  • Assist in the planning of the annual meeting scientific program and the review of submitted abstracts in the non-hematopoietic stem cell field.
  • Review the status of the MSC field and compile a list of major scientific issues that must be addressed to advance or enable cellular therapies utilizing MSCs.
  • Foster international discussion about controversies in the MSC field and method standardization.
  • Publish position papers and engage in scientific discourse as necessary to advance the field.



The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013 Jan;15(1):2-8. doi: 10.1016/j.jcyt.2012.10.002.

Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018 Jun 1;22(6):824-833. doi: 10.1016/j.stem.2018.05.004. Review.

2017 MSC Trials (Members only)

A relativity concept in mesenchymal stromal cell manufacturing. (Cytotherapy 2016 May;18(5):613-20.)

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. (Cytotherapy 2016 Feb;18(2):151-9.)

Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. (Cytotherapy 2013 Sep;15(9):1054-61.)

MSCs: science and trials. (Nat Med. 2013 Jul;19(7):812.)

Mesenchymal stromal cells: misconceptions and evolving concepts. (Cytotherapy 2013 Feb;15(2):140-5.)

Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. (Cell Stem Cell. 2012 Jan 6;10(1):9-10; author reply 10-1.)

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement (Cytotherapy 2006, 8(4): 315-317)


Committee Members:



Jacques Galipeau, MD
Chair (June 2016- Present)
University of Wisconsin-Madison
Madison, WI, United States
Co-Chair, ISCT 2016 Annual Meeting

Mauro Krampera, MD
University of Verona
Verona, Italy

Katarina Le Blanc, MD, PhD
Karolinska University Hospital
Stockholm, Sweden

Ivan Martin, PhD
University Hospital Basel
Basel, Switzerland
Co-Chair, ISCT 2020 Annual Meeting

 Jan Nolta, PhD
UC Davis - Stem Cell Program
Sacramento, CA, United States
Co-Chair, ISCT 2018 MSC Pre-Conference Track Co-Chair

Donald G. Phinney, PhD
The Scripps Research Institute - Scripps Florida
Jupiter, FL, United States
Co-Chair, ISCT 2018/2019 MSC Pre-Conference Track

Yufang Shi, PhD
Shanghai Institutes for Biological Sciences
Shanghai, China
Co-Chair, ISCT 2019 MSC Pre-Conference Track  

Luc Sensebé, MD, PhD
Establissement Francais Du Sang EFS
Toulouse, France
Co-Chair, ISCT 2014 Annual Meeting; MSC Committee Chair 2011 – 2016

Sowmya Viswanathan, PhD
University Health Network
Toronto, ON, Canada
ISO/TC276 Liason Officer


© 2019 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy